CMC Markets (CMCX) shares rise 12.22% to 270.75p as it forecasts record FY22 income
CMC, which provides online trading and institutional platform technology, said it expects to report net operating income of approximately £280 million - that’s at the top end of guidance and a record performance outside of the pandemic period - for the 2022 financial year.
In a trading update, CMC said 4Q had been its strongest quarter of FY22, with active monthly trading client numbers continuing to remain at similar levels as reported earlier in the year.
Operating costs for FY22, excluding variable remuneration, are expected to be slightly higher at around £173m from £168m, with the increase primarily due to higher personnel costs. CMC’s FY22 results for the 12 months to 31 March 2022 will be announced on 9 June 2022.
Oxford BioDynamics (OBD) shares jump 36.41% to 24.3p as Director buys more shares
The biotechnology company focused on developing epigenetic biomarkers said Vulpes Testudo Fund and Vulpes Life Sciences Fund, which are both controlled by Non-Executive Director Stephen Diggle, have today bought 200,000 and 400,000 shares, respectively.
Vulpes Testudo Fund bought shares at 18.5p in a transaction worth £0.037m in total, while Vulpes Life Sciences Fund bought the shares at 18.8p each, worth £0.075,2m in total.
Both these transactions combined are worth a total of £0.112,2m. Through the holdings of both funds, Diggle now holds 16% stake. Both of the transactions occurred on Wednesday.
Journeo (JNEO) shares jump 34.43% to 142.5p as it secures largest agreement to date
Journeo, a company that provides information systems and technical services to transport operators and local authorities, has secured its largest agreement to date with First Bus UK.
The deal, which will initially run for three-years until March 2025, is expected to generate £9m in revenues and includes an option to extend the term by two years through to March 2027.
Once the roll-out phase is completed, it will take the total number of vehicles connected and using Journeo’s SaaS platform to over 13,000.T he contracted revenues under the agreement were included in management’s expectations of performance for the current financial year and add to the Company’s strong order book, providing further future revenue visibility, it outlined.
Avacta Group (AVCT) shares jump 17.42% to 104.5p as its JV secures new partnership
AffyXell Therapeutics, a joint venture that Avacta Group owns in partnership with Daewoong Pharmaceutical, has entered into a new collaboration agreement designed to improve the translation of AffyXell’s programmes into human trials and accelerate drug development.
Under the agreement, AffyXell will develop new immune disease in vivo models and carry out proof-of-concept and toxicity testing of its drug candidates with developed disease models.
The new models will benefit from Biocytogen’s platform for gene editing, which creates mouse models capable of producing human antibodies. The collaboration is designed to improve the translation of AffyXell’s programmes into human trials and to accelerate drug development.